A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes

Overview

Journal Front Mol Med

Date 2024 Aug 1

PMID 39086971

Authors

Henry H Nguyen

Marvin J Fritzler

Mark G Swain

Affiliations

Soon will be listed here.

Abstract

Autoimmune cholestatic liver disease includes both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). Both conditions result in impairment of hepatic bile flow ultimately leading to chronic liver injury, liver fibrosis and eventually end stage cirrhosis. Early and accurate diagnosis are important for the risk stratification, follow up and management of these patients. The underlying pathogenesis of these conditions have not been completely resolved and poses a barrier for the development of new diagnostic and prognostics tools. Current research work suggests that the pathogenesis of autoimmune cholestatic liver disease results from environmental, genetic, and a large component of underlying immune dysfunction. While the current available serum biomarkers and imaging modalities showcases progression in precision medicine for the management of autoimmune cholestatic liver disease, development of new biomarkers are still an area of need in this field. In this review, we will discuss the current and emerging biomarkers in patients with PBC, PSC, and a special population that exhibit overlap syndrome with autoimmune hepatitis (AIH). The use of these biomarkers for diagnosis and prognosis of these patients will be reviewed through the lens of the current understanding of the complex immune pathophysiology of these conditions.

Citing Articles

Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis.

Bajraktari G, Elger T, Huss M, Loibl J, Albert A, Kandulski A Int J Mol Sci. 2024; 25(9).

PMID: 38731984 PMC: 11084718. DOI: 10.3390/ijms25094765.

Top-Down Proteomics Detection of Potential Salivary Biomarkers for Autoimmune Liver Diseases Classification.

Olianas A, Guadalupi G, Cabras T, Contini C, Serrao S, Iavarone F Int J Mol Sci. 2023; 24(2).

PMID: 36674470 PMC: 9866740. DOI: 10.3390/ijms24020959.

References

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

Harada K, Tsuneyama K, Sudo Y, Masuda S, Nakanuma Y . Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation?. Hepatology. 2001; 33(3):530-6. DOI: 10.1053/jhep.2001.22653. View

Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q . Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2017; 67(3):534-541. DOI: 10.1136/gutjnl-2016-313332. View

Pisetsky D, Lipsky P . New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020; 16(10):565-579. PMC: 8456518. DOI: 10.1038/s41584-020-0480-7. View

Ruhlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M . Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019; 50(5):580-589. PMC: 6899739. DOI: 10.1111/apt.15375. View

Nguyen H, Shaheen A, Baeza N, Lytvyak E, Urbanski S, Mason A . Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS One. 2018; 13(3):e0193960. PMC: 5858776. DOI: 10.1371/journal.pone.0193960. View

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R . Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2005; 44(2):400-6. DOI: 10.1016/j.jhep.2005.10.017. View

Quraishi M, Acharjee A, Beggs A, Horniblow R, Tselepis C, Gkoutos G . A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. J Crohns Colitis. 2020; 14(7):935-947. PMC: 7392170. DOI: 10.1093/ecco-jcc/jjaa021. View

10.

Stinton L, Bentow C, Mahler M, Norman G, Eksteen B, Mason A . PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One. 2014; 9(11):e112877. PMC: 4232573. DOI: 10.1371/journal.pone.0112877. View

11.

Bogdanos D, Baum H, Grasso A, Okamoto M, Butler P, Ma Y . Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol. 2003; 40(1):31-9. DOI: 10.1016/s0168-8278(03)00501-4. View

12.

Little R, Wine E, Kamath B, Griffiths A, Ricciuto A . Gut microbiome in primary sclerosing cholangitis: A review. World J Gastroenterol. 2020; 26(21):2768-2780. PMC: 7284173. DOI: 10.3748/wjg.v26.i21.2768. View

13.

Lv L, Fang D, Shi D, Chen D, Yan R, Zhu Y . Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol. 2016; 18(7):2272-86. DOI: 10.1111/1462-2920.13401. View

14.

John B, Khakoo N, Schwartz K, Aitchenson G, Levy C, Dahman B . Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. Am J Gastroenterol. 2021; 116(9):1913-1923. PMC: 8410631. DOI: 10.14309/ajg.0000000000001280. View

15.

Acharya C, Bajaj J . Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol. 2018; 17(2):307-321. PMC: 6314917. DOI: 10.1016/j.cgh.2018.08.008. View

16.

Lemoinne S, Kemgang A, Belkacem K, Straube M, Jegou S, Corpechot C . Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2019; 69(1):92-102. DOI: 10.1136/gutjnl-2018-317791. View

17.

Quraishi M, Shaheen W, Oo Y, Iqbal T . Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease. Clin Exp Immunol. 2019; 199(1):24-38. PMC: 6904658. DOI: 10.1111/cei.13397. View

18.

Hu S, Zhao F, Hu Q, Chen W . Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014; 9(7):e101916. PMC: 4092088. DOI: 10.1371/journal.pone.0101916. View

19.

Bauer A, Habior A, Wieszczy P, Gawel D . Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis. Diagnostics (Basel). 2021; 11(4). PMC: 8064069. DOI: 10.3390/diagnostics11040587. View

20.

Abdulkarim A, Petrovic L, Kim W, Angulo P, Lloyd R, Lindor K . Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?. J Hepatol. 2004; 40(3):380-4. DOI: 10.1016/j.jhep.2003.11.033. View